Pablo Corral: Association of Lp(a) With Coronary Atherosclerosis and CV Events
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Elias Björnson et al., published in JACC: Cardiovascular Imaging, adding:
“Association of Lp(a) With Coronary Atherosclerosis and CV Events
Lp(a): perhaps more atherogenic than thrombogenic?
1. What does SCAPIS cohort tell us?
In gt;28,000 individuals followed for 7.8 years, high Lp(a) was associated with:
- More coronary atherosclerosis
- Earlier development of plaque
- More obstructive disease
- Approximatelly 50% higher risk of coronary events
But here is the key: At a similar plaque burden, high Lp(a) was NOT associated with more events. Mediation analysis suggested that most of the excess risk associated with Lp(a) was explained by greater atherosclerotic burden, with no significant direct effect on events.
2.Could this help us think about the negative Lp(a)HORIZON trial?
Perhaps.
If the major clinical effect of Lp(a) is to accelerate atherosclerosis over decades, rather than primarily triggering thrombosis on established plaques, then: Lowering Lp(a) late in the disease course may not rapidly reverse decades of accumulated plaque burden.
This does not rule out prothrombotic or plaque-vulnerability effects.
But it raises an important question after HORIZON: With Lp(a), could timing matter as much as lowering?”
Title: Association of Lipoprotein(a) With Coronary Atherosclerosis and Cardiovascular Events: Findings From the SCAPIS Cohort
Authors: Elias Björnson, Göran Bergström, Jonas Brinck, David Erlinge, Carl Johan Östgren, Stefan Söderberg, Tomas Jernberg, Jan Borén, Emil Hagström

Other featuring Pablo Corral on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series